$ 37.89
Key Takeaways
Risk factor
Significant default risk
Profitability factor
Very low or no dividends
About
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed...
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA, ov
Target Price
The average target price of KNSA is 45 and suggests 17% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
